Nuformix PLC - Director/PDMR Dealings

RNS Number : 0442L

Nuformix PLC

05 November 2024

5 November 2024

Nuformix plc

("Nuformix" or the "Company" or the "Group")

Director/PDMR Dealings

Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces further to the completion of the Placing and Subscription to raise gross proceeds of £300,000, as announced on 20 September 2024, and Admission of the New Ordinary Shares today, further details of the Directors' participation in the Fundarise.

Each of the Company's Directors have subscribed for the following New Ordinary Shares at the Issue Price:

Name	Position	Ordinary shares subscribed for	% held of enlarged share capital on Admission
Julian Gilbert	Non-Executive Chairman	22,000,000	1.57%
Maddy Kennedy	Non-Executive Director	22,000,000	1.57%
Dan Gooding	Executive Director	12,000,000	3.49%

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation (2014/596/EU) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 and as modified by or under the European Union (Withdrawal) Act 2018 or other domestic law, provides further detail.

Terms used in this announcement shall, unless the context otherwise requires, be as deﬁned in the Prospectus published by the Company on 16 October 2024.

Enquiries:

Nuformix plc
Dr Dan Gooding, Executive Director	Via IFC Advisory
CMC Markets
Douglas Crippen	+44 (0) 20 3003 8632

IFC Advisory Limited
Tim Metcalfe Zach Cohen	+44 (0) 20 3934 6630 nuformix@investor-focus.co.uk

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Julian Gilbert
2	Reason for the notification
a)	Position/status	Non-Executive Chairman
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Nuformix plc
b)	LEI	2138003XG3H3I2J3BJ24
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of nominal value 0.05 pence GB00BYW79Y38
b)	Nature of the transaction	Purchase of ordinary shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 0.05 pence 22,000,000
d)	Aggregated information - Aggregated volume - Price	22,000,000 £11,000
e)	Date of the transaction	5 November 2024
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Maddy Kennedy
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Nuformix plc
b)	LEI	2138003XG3H3I2J3BJ24
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of nominal value 0.05 pence GB00BYW79Y38
b)	Nature of the transaction	Purchase of ordinary shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 0.05 pence 22,000,000
d)	Aggregated information - Aggregated volume - Price	22,000,000 £11,000
e)	Date of the transaction	5 November 2024
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Dan Gooding
2	Reason for the notification
a)	Position/status	Executive Director
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Nuformix plc
b)	LEI	2138003XG3H3I2J3BJ24
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of nominal value 0.05 pence GB00BYW79Y38
b)	Nature of the transaction	Purchase of ordinary shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 0.05 pence 12,000,000
d)	Aggregated information - Aggregated volume - Price	12,000,000 £6,000
e)	Date of the transaction	5 November 2024
f)	Place of the transaction	Outside a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFFSLSLEIIS]]>